Table 10.
Antiproliferative activity of cisplatin, equimolar mixtures of cisplatin and naproxen, and platinum(IV) prodrugs 21 and 10 on MCF-7 (breast cancer), MDA-MB-231 (triple negative breast adenocarcinoma), and MDA-MB-435 (triple negative breast adenocarcinoma) cell lines.
| Compound/Cell Line | IC50, µM | ||
|---|---|---|---|
| MCF-7 | MDA-MB-231 | MDA-MB-435 | |
| 21 | 0.17 ± 0.04 | 0.16 ± 0.01 | 0.34 ± 0.09 |
| 10 | 0.40 ± 0.10 | 0.81 ± 0.02 | 1.11 ± 0.06 |
| Cisplatin | 4.00 ± 1.00 | 29.98 ± 1.10 | 8.34 ± 0.49 |
| Cisplatin + Naproxen | 7.00 ± 2.00 | >64 | >32 |
| Cisplatin + 2 Naproxen | 5.18 ± 2.80 | >64 | >32 |
| Naproxen | >64 | >64 | >64 |